IL6 and neoplasm: The recently identified heterodimeric member of the IL-6/IL-12 family of cytokines [1,2] namely interleukin (IL)-27, has revealed potent anti-tumor effects in various tumor models and, importantly, freedom from toxicity in preclinical trials [3].